We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
You must tell DVLA if you have muscular dystrophy - download the correct form to let them know.
Projects granted during 2014 that have a primary purpose of basic research into the musculoskeletal system.
National data on the prevalence of spinal muscular atrophy type 1 (SMA1) from the National Congenital Anomaly and Rare Disease Registration Service.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (20 December 2024) granted a conditional marketing authorisation for the medicine givinostat (Duvyzat) to treat Duchenne muscular dystrophy (DMD).
Projects granted during 2015 that have a primary purpose of basic research: musculoskeletal system.
This profile provides data on musculoskeletal conditions and services for local populations in England.
Information and resources on musculoskeletal health conditions.
Check if you need to tell DVLA about a health or medical condition, how to report medical conditions to DVLA
Report certain types of medical conditions to DVLA if you're a car driver or motorcyclist.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).